Repatha vs Lisinopril: Switching Between Them

Why These Two Drugs Are Not Direct Competitors

Repatha and lisinopril occupy different pharmacologic categories and target separate cardiovascular risk pathways. Comparing them head-to-head misframes how clinicians actually use these medications. They are complementary far more often than they are alternatives.

Evolocumab (brand name Repatha) belongs to the PCSK9 inhibitor class. It binds proprotein convertase subtilisin/kexin type 9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab increases the number of LDL receptors available to clear circulating LDL-C from the bloodstream. The result is a rapid, pronounced drop in LDL cholesterol.

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. The downstream effect: reduced blood pressure, decreased aldosterone secretion, and lower afterload on the heart. The ALLHAT trial (N=33,357) tested lisinopril against chlorthalidone and amlodipine for hypertension outcomes and found equivalent primary coronary heart disease event rates, though lisinopril showed a higher stroke incidence compared to chlorthalidone in that population.

No randomized controlled trial has directly compared evolocumab to lisinopril. None is likely to be designed, because the drugs answer different clinical questions. A patient with an LDL of 190 mg/dL on maximally tolerated statin therapy and normal blood pressure needs evolocumab, not lisinopril. A patient with stage 2 hypertension and an LDL of 85 mg/dL needs lisinopril, not evolocumab. The rare scenario where a "switch" applies involves patients whose risk profile has shifted or whose side effects demand a medication change.

Mechanism of Action: Two Separate Pathways

Each drug intervenes at a distinct point in cardiovascular pathophysiology. Understanding these mechanisms explains why substituting one for the other seldom makes clinical sense.

Evolocumab works exclusively on lipid metabolism. PCSK9 normally tags LDL receptors for lysosomal degradation after they internalize an LDL particle. When evolocumab binds PCSK9, those receptors recycle to the hepatocyte surface and continue clearing LDL from plasma. In the FOURIER trial, this mechanism produced a median LDL reduction from 92 mg/dL to 30 mg/dL at 48 weeks [1]. That 59% reduction translated to a 15% relative risk reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

Lisinopril acts on the renin-angiotensin-aldosterone system (RAAS). By inhibiting ACE, it reduces angiotensin II levels, which relaxes arterial smooth muscle, decreases sodium reabsorption, and lowers systemic vascular resistance. A meta-analysis of ACE inhibitor trials demonstrated that this class reduces blood pressure by approximately 8 to 10 mmHg systolic on average, with secondary benefits for left ventricular remodeling and renal protection in diabetic nephropathy [2].

The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease treats hypertension management and lipid management as parallel workstreams, each with its own treatment algorithm [3]. A patient may need both an ACE inhibitor and a PCSK9 inhibitor simultaneously. Stopping one to start the other leaves an entire risk factor uncontrolled.

Clinical Evidence: FOURIER vs ALLHAT

These two landmark trials illustrate the divergent roles of evolocumab and lisinopril in cardiovascular risk reduction. Neither trial tested the other drug. Cross-trial comparisons carry significant methodological limitations, but examining each trial's design and results clarifies what each medication can and cannot do.

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving statin therapy. Patients were randomized to evolocumab 140 mg every two weeks (or 420 mg monthly) versus placebo. At a median follow-up of 2.2 years, the primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of placebo (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [1]. The trial population had a mean baseline LDL of 92 mg/dL despite statin use.

ALLHAT enrolled 33,357 patients aged 55 and older with hypertension and at least one additional coronary heart disease risk factor. The lisinopril arm (N=9,054) was compared primarily to chlorthalidone (N=15,255). The primary outcome of fatal CHD or nonfatal MI showed no significant difference between lisinopril and chlorthalidone (RR 0.99, 95% CI 0.91 to 1.08) [4]. The lisinopril arm did show a higher 6-year rate of stroke (6.3% vs 5.6%, RR 1.15, P=0.02) and combined CVD (33.3% vs 30.9%, RR 1.10, P<0.001) compared to chlorthalidone, which led guideline panels to position thiazide diuretics ahead of ACE inhibitors as first-line antihypertensives in certain populations.

These trials answer different questions. FOURIER asked: does adding a PCSK9 inhibitor to statin therapy reduce events in established ASCVD? ALLHAT asked: among first-line antihypertensives, which class produces the best outcomes? Mixing conclusions from the two studies to argue that "Repatha is better than lisinopril" or vice versa misrepresents both datasets.

When a True Switch Might Be Considered

Switching from Repatha to lisinopril (or vice versa) is an uncommon clinical decision. A true one-for-one swap only arises under specific circumstances.

The most plausible switching scenario involves a patient who was started on one medication prematurely or based on an incomplete risk assessment. For example, a patient placed on evolocumab for borderline high LDL who is later found to have stage 2 hypertension and an LDL that responds adequately to a statin alone may benefit from discontinuing the PCSK9 inhibitor and starting an ACE inhibitor instead. The reverse scenario could involve a hypertensive patient on lisinopril who develops familial hypercholesterolemia or statin intolerance with persistently elevated LDL, prompting addition of (not switch to) evolocumab.

Side effects occasionally force discontinuation. Lisinopril causes a dry, persistent cough in approximately 10% to 15% of patients due to bradykinin accumulation [5]. Angioedema, though rare (0.1% to 0.7%), is a potentially life-threatening adverse effect. In these cases, the replacement is typically an angiotensin receptor blocker (ARB), not a PCSK9 inhibitor. Evolocumab's most common adverse effects are injection-site reactions (reported in 3% to 5% of patients in clinical trials) and upper respiratory symptoms. Discontinuation for side effects usually leads to a trial of alirocumab or inclisiran, not an ACE inhibitor.

The 2018 AHA/ACC cholesterol guideline positions PCSK9 inhibitors as add-on therapy for patients with ASCVD or familial hypercholesterolemia who have not reached their LDL goal on maximally tolerated statin plus ezetimibe [6]. Lisinopril does not appear in the lipid management algorithm. The 2017 ACC/AHA hypertension guideline lists ACE inhibitors among four first-line antihypertensive classes [7]. Evolocumab does not appear in the blood pressure algorithm. These two documents underscore that the drugs treat parallel, not overlapping, indications.

Cost and Insurance: A Practical Comparison

Cost differences between these two medications are extreme, and financial considerations sometimes drive prescribing decisions more than pharmacology does.

Generic lisinopril is one of the most affordable cardiovascular medications available. A 30-day supply of lisinopril 10 mg costs between $4 and $15 at most U.S. pharmacies without insurance. It appears on virtually every formulary at the lowest tier. No prior authorization is required.

Repatha carries a wholesale acquisition cost of approximately $5,850 per year. While Amgen's net pricing after rebates may be lower, patients face prior authorization requirements from nearly all commercial payers. The FDA approval for evolocumab covers homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), and established ASCVD in patients requiring additional LDL lowering [8]. Insurers typically require documentation that a patient has tried and failed maximally tolerated statin therapy plus ezetimibe before covering a PCSK9 inhibitor.

A patient whose LDL is adequately controlled on a statin and who primarily needs blood pressure management will find lisinopril dramatically more accessible from both a formulary and out-of-pocket standpoint. A patient with refractory hypercholesterolemia who does not have hypertension gains nothing from lisinopril. The cost comparison is real, but it is only clinically meaningful when both drugs could plausibly treat the same patient's primary risk factor.

Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular, and Thoracic Institute at Cleveland Clinic, has stated: "PCSK9 inhibitors are not a substitute for foundational cardiovascular therapies like ACE inhibitors or statins. They fill a specific gap in patients who cannot reach their LDL targets with oral agents alone."

Side Effect Profiles: What to Expect With Each Drug

The adverse event profiles of these medications differ substantially, reflecting their unrelated mechanisms.

Lisinopril's side effects stem from ACE inhibition and its effects on bradykinin metabolism. The ACE inhibitor cough is the most frequent reason for discontinuation. It is nonproductive, often worse at night, and resolves within one to four weeks of stopping the drug [5]. Hyperkalemia can occur, particularly in patients with chronic kidney disease or those taking potassium-sparing diuretics. First-dose hypotension is a known risk, especially in volume-depleted patients. Acute kidney injury may occur in patients with bilateral renal artery stenosis. Angioedema occurs more frequently in Black patients, with incidence rates up to three to four times higher than in White patients in some datasets [9].

Evolocumab is generally well-tolerated. In FOURIER, discontinuation rates due to adverse events were similar between evolocumab and placebo (1.6% vs 1.5%). Injection-site reactions occurred in approximately 2.1% of patients in the evolocumab group vs 1.6% in placebo. Early concerns about neurocognitive effects were addressed by the EBBINGHAUS substudy, which found no significant difference in cognitive function between evolocumab and placebo over a median of 19 months [10]. Nasopharyngitis, upper respiratory tract infection, and back pain were reported at similar rates in both groups.

The practical takeaway: lisinopril side effects are more common but usually manageable with a switch to an ARB. Evolocumab side effects are less frequent but the drug requires subcutaneous injection, which some patients find burdensome.

Using Both Drugs Together

For many patients with established ASCVD and coexisting hypertension, the answer is not Repatha or lisinopril. It is both.

The 2019 ACC/AHA primary prevention guideline and the 2018 cholesterol management guideline both support multifactorial risk reduction [3][6]. A patient with prior MI, LDL of 95 mg/dL on rosuvastatin 40 mg plus ezetimibe, and blood pressure of 148/92 mmHg could appropriately receive both evolocumab and lisinopril. No pharmacokinetic interaction exists between a monoclonal antibody (evolocumab) and a small-molecule ACE inhibitor (lisinopril). They are metabolized through completely different pathways.

Dr. Paul Ridker, Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has noted: "Cardiovascular prevention requires treating all modifiable risk factors simultaneously. Lowering LDL without controlling blood pressure, or controlling pressure without addressing lipids, leaves residual risk on the table."

Real-world prescribing data from the GOULD registry showed that among patients started on PCSK9 inhibitors, over 70% were already taking at least one antihypertensive agent [11]. Combination therapy with drugs from both classes is the norm in high-risk secondary prevention, not the exception.

How to Transition if Your Doctor Recommends a Change

If your clinician determines that adding or removing one of these drugs is appropriate, the transition process differs depending on the direction of the change.

Starting evolocumab while continuing lisinopril requires no washout period. The PCSK9 inhibitor can be initiated at 140 mg subcutaneously every two weeks or 420 mg monthly. LDL should be rechecked at 4 to 8 weeks to confirm response. No dose adjustment of lisinopril is needed.

Discontinuing evolocumab while adding lisinopril (a rare scenario) should account for the fact that LDL-C will begin rising within two to four weeks of stopping the PCSK9 inhibitor, as PCSK9 levels rebound and LDL receptor degradation resumes. If the rationale for stopping evolocumab is cost or insurance denial, the patient's lipid panel must be monitored closely over the subsequent 8 to 12 weeks to determine whether alternative lipid-lowering therapy (bempedoic acid, inclisiran, or bile acid sequestrant) is needed.

Lisinopril initiation typically starts at 5 mg or 10 mg daily, with blood pressure and serum creatinine/potassium checked within one to two weeks. Uptitration to 20 to 40 mg daily depends on blood pressure response and tolerability. ACE inhibitor therapy should not be started in patients with a serum potassium above 5.5 mEq/L or an eGFR declining rapidly without nephrologic evaluation.

Patients should not self-switch between these medications. The decision to start, stop, or substitute either drug requires clinical assessment including current LDL-C, blood pressure, renal function, potassium, and a reassessment of 10-year ASCVD risk using the Pooled Cohort Equations.